

Special Issue

Cellular Immune Response to Hepatitis Viruses

Message from the Guest Editor

The liver maintains a delicate balance between immunological tolerance and the elimination of pathogens. Disruption of this balance can lead to hepatitis and severe complications. Besides classical hepatitis A–E viruses (HAV, HBV, HCV, HDV, HEV), various emerging and re-emerging agents, including yellow fever (YFV), dengue (DENV), Zika (ZIKV), Crimean–Congo hemorrhagic fever (CCHFV), Rift Valley fever (RVFV), Lassa (LASV), and Ebola (EBOV), also target the liver and contribute to the global burden of viral hepatitis. Understanding how these viruses interact with and evade immune responses is crucial for developing novel prophylactic and therapeutic strategies. This Special Issue, “Cellular Immune Response to Hepatitis Viruses,” will focus on recent developments in viral sensing, immune evasion, immunopathology, immunomodulatory agents, and preclinical models for studying hepatotropic viruses. We invite submissions of original research, short communications, and review articles in this dynamic field. We look forward to your contributions.

Guest Editor

Dr. Armando Andres Roca Suarez

1. Inserm, UMR 1350 PaThLiv, Université Claude-Bernard Lyon 1, F-69003 Lyon, France
2. The Lyon Hepatology Institute, IHU EVEREST, F-69004 Lyon, France

Deadline for manuscript submissions

30 November 2026



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/249282

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).